Sold as Furoxone. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Furazolidone (sold as Furoxone), first approved Jan 20, 1958, with 0 new uses approved and 0 published complete response letters.
| Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue TreatmentGastritis, Dyspepsia · Yongquan Shi | Phase 4 | Recruiting | Aug 24, 2025 |
| The Efficacy and Safety of Keverprazan for Helicobacter Pylori EradicationHelicobacter Pylori Infection · Nanjing First Hospital, Nanjing Medical University | Early phase 1 | Not yet recruiting | Jan 16, 2025 |
| Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue TreatmentHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education · Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | Not yet recruiting | Jan 6, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
